Newron starts patient enrollment for Phase III trial on treatment-resistant schizophrenia

Wednesday, August 13, 2025 @ 12:00 am

Newron started patient enrollment for ENIGMA-TRS 1, the first of two phase III trials in the ENIGMA-TRS development program, evaluating evenamide as an add-on therapy for TRS, including CTRS, and those with poorly responding schizophrenia. Topline results are expected in Q4 2026.

Key catalysts include:

1. H1 2025 results (16 September 2025)
2. Start ENIGMA-TRS 2 phase III evenamide TRS trial (October 2025)
3. Partnering evenamide with CNS players in non-core markets (during 2025)

Newron Flash Update

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Pharvaris: Second quarter 2025 financial results and business update

Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026 Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AA
August 12, 2025

Mabylon: CHF 30 million to advance peanut allergy lead program

Funding combines equity investment and convertible loan. Focus on best-in-class, clinical-stage peanut allergen-neutralizing antibody MY006. Further potential for developing Mabylon’s discovery and pre-clinical pipeline programs. These include MY010, a multi-specific and cross-reactive antibody targeting the birch Bet v 1 allergen, as well as all the major birch-related tree, fruit and nuts alle
August 12, 2025

Indian-Swiss agricultural partnership: AgrINovo

Novochizol, Aquagri and its partner companies today announced the launch of AgrINovo, a transformative collaborative project. AgrINovo aims to unlock the full potential of Novochizol technology to foster a healthier, more sustainable agriculture in India and worldwide.
August 4, 2025

Memo Therapeutics: Phase II trial results from kidney transplant recipients with virus infection

Phase II results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients, with no safety or tolerability concerns observed. Results support progression into Phase III development with the potential to transform the treatment landscape for kidney transplant patients with BK polyomavirus infection.
July 25, 2025

Cosmo flash update: Key products shine - upgraded EBITDA target

July 24, 2025